Abstract
Low-density lipoprotein receptor–related protein-1 (LRP) on brain capillaries clears amyloid β-peptide (Aβ) from brain. Here, we show that soluble circulating LRP (sLRP) provides key endogenous peripheral 'sink' activity for Aβ in humans. Recombinant LRP cluster IV (LRP-IV) bound Aβ in plasma in mice and Alzheimer's disease–affected humans with compromised sLRP-mediated Aβ binding, and reduced Aβ-related pathology and dysfunction in a mouse model of Alzheimer disease, suggesting that LRP-IV can effectively replace native sLRP and clear Aβ.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
£139.00 per year
only £11.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Shibata, M. et al. J. Clin. Invest. 106, 1489–1499 (2000).
Deane, R. et al. Neuron 43, 333–344 (2004).
Tanzi, R.E., Moir, R.D. & Wagner, S.L. Neuron 43, 605–608 (2004).
Bell, R.D. et al. J. Cereb. Blood Flow Metab. 27, 909–918 (2007).
Tamaki, C. et al. Pharm. Res. 23, 1407–1416 (2006).
von Arnim, C.A.F. et al. J. Biol. Chem. 280, 17777–17785 (2005).
Quinn, K.A. et al. J. Biol. Chem. 272, 23946–23951 (1997).
Westein, E., Denis, C.V., Bouma, B.N. & Lenting, P.J. J. Biol. Chem. 277, 2511–2516 (2002).
Deane, R. et al. Nat. Med. 9, 907–913 (2003).
Zerbinatti, C.V. & Bu, G.J. Rev. Neurosci. 16, 123–135 (2005).
Jensen, G.A. et al. J. Mol. Biol. 362, 700–716 (2006).
Kumar-Singh, S. et al. Am. J. Pathol. 167, 527–543 (2005).
Hsiao, K. et al. Science 274, 99–102 (1996).
Fryer, J.D. et al. J. Neurosci. 25, 2803–2810 (2005).
Matsuoka, Y. et al. J. Neurosci. 23, 29–33 (2003).
Acknowledgements
This work was supported by US National Institutes of Health (NIH) grants R37 AG023084 and R37 NS34467 to B.V.Z. and Washington University St. Louis Alzheimer's Disease Research Center grant P50 AG05681.
Author information
Authors and Affiliations
Contributions
A.S. conducted and performed in vivo studies in wild-type and APP+/sw (APPsw+/−) mice. R.D. conducted and performed pharmacokinetic and cerebral blood flow studies and work on the human study protocol. R.D.B. conducted and performed in vitro ligand binding assays and Aβ immunostaining studies. B.J. performed the oxidized sLRP assay and sLRP ELISA assay. K.H. performed in vivo studies in wild-type mice. R.P. purified recombinant LRP-IV. A.M. performed cholesterol and apoE assays. P.J.L. supervised R.P. and provided LRP-IV. Z.W. conducted and performed memory tests in mice. T.Z. performed approach and operant learning test in mice. D.P. performed active tPA and pro-MMP-9 assays. A.G. and K.M. performed LRP polymorphism studies. M.C. performed immunoprecipitation of oxidized proteins. Z.Z. performed Prussian blue staining. B.V.Z. designed the entire study, supervised all portions of the study and wrote the manuscript.
Corresponding author
Ethics declarations
Competing interests
B.V.Z. is Scientific Founder and Program Director of Socratech LLC, a startup biotechnology company with a mission to develop therapeutics for Alzheimer's disease, stroke and other neurodegenerative disorders, and owns shares in the company. He does not receive direct financial compensation from Socratech LLC.
Supplementary information
Supplementary Text and Figures
Supplementary Figs. 1–7, Supplementary Table 1 and Methods (PDF 8244 kb)
Rights and permissions
About this article
Cite this article
Sagare, A., Deane, R., Bell, R. et al. Clearance of amyloid-β by circulating lipoprotein receptors. Nat Med 13, 1029–1031 (2007). https://doi.org/10.1038/nm1635
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm1635
This article is cited by
-
Anti-malaria drug artesunate prevents development of amyloid-β pathology in mice by upregulating PICALM at the blood-brain barrier
Molecular Neurodegeneration (2023)
-
Inhibition of ACAT as a Therapeutic Target for Alzheimer's Disease Is Independent of ApoE4 Lipidation
Neurotherapeutics (2023)
-
Effect of the ABCA1 agonist CS-6253 on amyloid-β and lipoprotein metabolism in cynomolgus monkeys
Alzheimer's Research & Therapy (2022)
-
Delineation of Neuroprotective Effects and Possible Benefits of AntioxidantsTherapy for the Treatment of Alzheimer’s Diseases by Targeting Mitochondrial-Derived Reactive Oxygen Species: Bench to Bedside
Molecular Neurobiology (2022)
-
PCSK9 acts as a key regulator of Aβ clearance across the blood–brain barrier
Cellular and Molecular Life Sciences (2022)